Adhesion molecules and differentiation syndrome: Phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia

Haematologica

Volumn 92, Issue 12, 2007, Pages 1615-1622

  De Santis, Gil Cunha ^a   Tamarozzi, Mirela De Barros ^a   Sousa, Romualdo Barroso ^a   Moreno, Susana Elisa ^a   Secco, Daniela ^a   Garcia, Aglair Bergamo ^a   Lima, Ana Sílvia Gouveia ^a   Faccioli, Lúcia Helena ^a   Falcão, Roberto Passetto ^a   Cunha, Fernando Queirós ^a   Rego, Eduardo Magalhães ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute promyelocytic leukemia; Adhesion molecules; G CSF; Histone deacetylase inhibitor

Indexed keywords

ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; CD11B ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MATRIGEL; MYELOPEROXIDASE; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATION SYNDROME; DISEASE SEVERITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG; LUNG BLOOD VESSEL; LYMPHOBLAST; MOUSE; NONHUMAN; PHENOTYPE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINOIC ACID SYNDROME; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL ADHESION; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM PROTEINS; OXIDES; PHENYLBUTYRATES; SYNDROME; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 37049011854     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10607     Document Type: Article

References (34)

1. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-4.
2. Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, Minucci S, Pelicci PG, et al. Retinole acid receptor a fusion to PML affects its transcriptional and chromatin-remodeling properties. Mol Cell Biol 2003; 23: 8795-808.
3. Degos L. The history of acute promyelocytic leukaemia. Br J Haematol 2003;122:539-53.
4. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998;92:2712-8.
5. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP, Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
6. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description or 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000;95:90-5.
7. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol 2003; 16:453-61.
8. Brown DC, Tsuji H, Larson RS. All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow. Br J Haematol 1999;107:86-98.
9. Zang C, Liu H, Ries C, Ismair MG, Petrides PE. Enhanced migration of the acute promyelocytic leukemia cell line NB4 under in vitro conditions during short-term all-transretinoic acid treatment. J Cancer Res Clin Oncol 2000;126:33-40.
10. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43.
11. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP, Jr., Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002;99:1356-63.
12. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-302.
13. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
14. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345-53.
15. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-30.
16. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
17. Bradstock KF. The use of hematopoietic growth factors in the treatment of acute leukemia. Curr Pharm Des 2002;8:343-55.
18. Glaspy JA, Golde DW. Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. Semin Oncol 1992;19:386-94.
19. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52.
20. Jansen JH, de Ridder MC, Geertsma WM, Erpelinck CA, van Lom K, Smit EM, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1999; 94:39-45.
21. Bullard DC, Qin L, Lorenzo I, Quinlin WM, Doyle NA, Bosse R, et al. P-selectin/ICAM-1 double mutant mice: acute emigration of neutrophils into the peritoneum is completely absent but is normal into pulmonary alveoli. J Clin Invest 1995;95:1782-8.
22. Wilson RW, Ballantyne CM, Smith CW, Montgomery C, Bradley A, O'Brien WE, et al. Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol 1993;151:1571-8.
23. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
24. Wyman TH, Bjornsen AJ, Elzi DJ, Smith CW, England KM, Kelher M, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002; 283:C1592-603.
25. McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 2003;10:150-8.
26. Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica 2007;92:289-91.
27. Rego EM, He LZ, Warrell RP, Jr., Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000;97:10173-8.
28. Hong SH, Yang Z, Privalsky ML. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor a oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001;21:7172-82.
29. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328-35.
30. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005;105:341-9.
31. Higuchi T, Kizaki M, Omine M. Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. Leuk Res 2004;28:525-32.
32. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997;90:2747-56.
33. Krieglstein CF, Anthoni C, Laukotter MG, Rijcken E, Spiegel HU, Senninger N, et al. Effect of anti-CD11b (aM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats. Int J Colorectal Dis 1999; 14:219-23.
34. Moreno SE, Alves-Filho JC, Alfaya TM, da Silva JS, Ferreira SH, Liew FY. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J Immunol 2006; 177:3218-24.